Back to list

AI Autonomous Laboratory: Making Protein R&D Think and Decide

Published on November 12, 2026

AI Autonomous Laboratory: Making Protein R&D Think and Decide

 Fig. 1: Overview of the AI autonomous laboratory (unattended automated pipeline)



Abstract: An AI Autonomous Laboratory (also known as a “lights-out laboratory”) uses a conversational agent as the brain and strings an automated line into a Design–Validate–Iterate dry-wet loop, compressing the protein R&D cycle from 3–5 years to 2–6 months and lifting the hit rate from below 5% to above 40%. This article explains its autonomy, the full solution, and the three automation platforms.  


Many read “lights-out laboratory” as “no one on site”, but what is truly scarce is not unattended operation — it is autonomy: the AI decides what to do next.


Start by separating two things. Automation answers “can it be done, and is it stable”; autonomy answers “what should be done next, and is it worth doing”. A machine that automatically loads samples 7×24 is still “executing a script”; only when an AI layer is added that actively plans and decides the next round of experiments does it deserve to be called an “autonomous laboratory”.


What an AI autonomous laboratory solves: the “scale-up” difficulty of protein R&D

Conventional R&D relies on expert intuition plus mass trial-and-error: a 3–5 year cycle, tens of thousands of experiments, a hit rate below 5%, and design and experiment often in two separate worlds — the AI produces candidates, yet they stall at manually scheduling experiments, hand-collecting data and poor feedback. This “can design, hard to scale” gap is exactly why an autonomous laboratory matters.

 

Autonomy ladder and the DBTL dry-wet loop.

Fig. 2: Autonomy ladder and the DBTL dry-wet loop


The complete solution: a pipeline that “thinks”

To turn autonomy into a deliverable capability, we provide a complete solution made up of a thinking “agent” and a modular automated line:


Complete solution: the dry-wet closed-loop R&D platform

A Design–Build–Test–Learn cycle that runs automatically: the model designs candidates on the “dry” side, the automation platforms validate quickly on the “wet” side, and results flow back automatically to drive the next round of design. MatwingsVenus®, a conversational agent, decides what to do: state your need in natural language, and it automatically breaks down the task, calls 200+ protein design tools, searches 10 billion real labelled data points, and orchestrates the whole experimental workflow.


Plasmid construction & extraction automation platform

The upstream start of the line. It performs gene cloning, plasmid construction and extraction, turning designed sequences into usable plasmids — the entry point of the fully automated workflow.


Protein expression automation platform

Covers inoculation, induction and cell harvesting, determining the yield and state of the protein;


Protein purification automation platform

Performs cell disruption, centrifugation, purification and quantitation, producing the target protein and connecting to functional assay.


Two full-process routes and deployment

The synthetic-biology solution and the biomedicine solution can be cross-configured, covering enzyme engineering, recombinant proteins, antibodies and biologics. Deployment supports cloud or private modes to keep sequences, designs and experimental data inside the enterprise boundary; locally it covers 50+ database interfaces plus structure prediction, molecular docking, enzyme engineering and molecule/antibody design. We also offer FDE (domain expert + AI engineer + data engineer) joint delivery, expert collaboration, and “validate with a sample before scale-up”.


How to judge “autonomy”?

Look at four things: can it auto-plan the next round (autonomous planning), can it pick the candidates most worth testing (autonomous decision-making), can it update itself from results (autonomous learning), and can it retry or switch route on anomalies (autonomous correction). Missing any one is “automation”, not “autonomy”.

 

Running workflow and quality gates of an unattended pipeline.

Fig. 3: Running workflow and quality gates of an unattended pipeline


FAQ

· How is it different from a “fully automatic machine”?  

Fully automatic just “executes a script”; autonomy is “knowing what to do” — on top of automated execution, it adds the AI’s active planning, decision-making and learning for the next round.

· What does the complete solution include?

 A dry-wet closed-loop R&D platform plus three automation platforms (plasmid construction & extraction, protein expression, protein purification), configurable along synthetic-biology or biomedicine routes, with private deployment supported.

· Can it be used with limited data?  

Yes. The platform locally covers 50+ database interfaces and several prediction/design capabilities; small data can be modelled incrementally with transfer learning and Bayesian optimisation — the key is structured, traceable data.


Summary

The value of an AI autonomous laboratory is not the “unattended” label, but turning a continuously iterating R&D capability into a reusable asset: judgement to AI, repetition to machines, creativity to people. What Matwings Technology and MatwingsVenus®  aim to do is make the “design–learn” side smarter and make “autonomy” truly practical.

Scan to join community

Scan to join community